Systemic AL (light chain) amyloidosis is a rare protein misfolding disorder associated with
plasma cell dyscrasia affecting various organs leading to organ dysfunction and failure. The …

Background There is ongoing uncertainty around the most suitable recall period for patient-
reported outcome measures (PROMs). Method This systematic review integrates …

Objective: Review literature on facial feminization surgery (FFS) for the transgender
population and identify whether heterogeneity in reported outcomes and outcome measures …

Background Light chain (AL) amyloidosis, a rare and life-threatening protein misfolding
disorder, causes organ damage and severely impacts health-related quality of life (HRQoL) …

We sought to evaluate how PROMIS patient-reported outcome (PRO) measures correlated
with disease characteristics in systemic light chain (AL) amyloidosis patients at diagnosis …

Objective To assess the impact of organ involvement on patient‐reported outcomes (PROs)
in light chain (AL) amyloidosis. Methods PROs were evaluated using the KCCQ‐12 …

Patient‐reported outcomes in AL amyloidosis have not been well‐studied. We analyzed
health‐related quality of life (HRQOL) and AL amyloidosis symptoms data from the phase 3 …

Purpose The purpose of this study was to conduct cognitive debriefing (CD) interviews with
adults diagnosed with chronic hypoparathyroidism (HP) to assess the content validity of the …

In the phase 3 ANDROMEDA trial, patients treated with daratumumab, bortezomib,
cyclophosphamide, and dexamethasone (D‐VCd) had significantly higher rates of organ …

Systemic AL amyloidosis is an incurable condition with various presentations and may
cause multiple complications related to organ involvement. As survival has improved …